Kliniske aspekter af Marfans syndrom

Tina Zimmermann Belsing; Allan Meldgaard Lund; Lars Søndergaard; Lennart Friis-Hansen; Steen Zabell Abildstrøm

Kliniske aspekter af Marfans syndrom

Translated title of the contribution: [Clinical aspects of Marfan syndrome]

Tina Zimmermann Belsing, Allan Meldgaard Lund, Lars Søndergaard, Lennart Friis-Hansen, Steen Zabell Abildstrøm

1 Citation (Scopus)

Abstract

Marfan syndrome (MFS) and MFS-related diseases are inherited connective tissue disorders involving several organ systems. The diagnosis of MFS is difficult as the many symptoms overlap with those of other systemic connective tissue diseases. The phenotype is progressive. Effective surgical therapy and standardized follow-up programs have led to an improved lifespan for the affected individuals. Selective angiotensin II, type 1 (AT1) blockers may improve several manifestations of MFS, but the outcome of clinical trials is presently unknown. This review describes the importance of a coordinated strategy for diagnosis, treatment and follow-up.

Translated title of the contribution	[Clinical aspects of Marfan syndrome]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	173
Issue number	5
Pages (from-to)	337-42
Number of pages	6
ISSN	0041-5782
Publication status	Published - Jan 2011

Access to Document

http://www.ugeskriftet.dk.ep.fjernadgang.kb.dk/portal/page/portal/LAEGERDK/UGESKRIFT_FOR_LAEGER/Artikelvisning?pUrl=/UGESKRIFT_FOR_LAEGER/TIDLIGERE_NUMRE/2011/UFL_2011_5/UFL_2011_173_5_337

Cite this

@article{3c85282ec236477e8c17014cc5d7c9b6,

title = "Kliniske aspekter af Marfans syndrom",

abstract = "Marfan syndrome (MFS) and MFS-related diseases are inherited connective tissue disorders involving several organ systems. The diagnosis of MFS is difficult as the many symptoms overlap with those of other systemic connective tissue diseases. The phenotype is progressive. Effective surgical therapy and standardized follow-up programs have led to an improved lifespan for the affected individuals. Selective angiotensin II, type 1 (AT1) blockers may improve several manifestations of MFS, but the outcome of clinical trials is presently unknown. This review describes the importance of a coordinated strategy for diagnosis, treatment and follow-up.",

author = "Belsing, {Tina Zimmermann} and Lund, {Allan Meldgaard} and Lars S{\o}ndergaard and Lennart Friis-Hansen and Abildstr{\o}m, {Steen Zabell}",

year = "2011",

month = jan,

language = "Dansk",

volume = "173",

pages = "337--42",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "5",

}

TY - JOUR

T1 - Kliniske aspekter af Marfans syndrom

AU - Belsing, Tina Zimmermann

AU - Lund, Allan Meldgaard

AU - Søndergaard, Lars

AU - Friis-Hansen, Lennart

AU - Abildstrøm, Steen Zabell

PY - 2011/1

Y1 - 2011/1

N2 - Marfan syndrome (MFS) and MFS-related diseases are inherited connective tissue disorders involving several organ systems. The diagnosis of MFS is difficult as the many symptoms overlap with those of other systemic connective tissue diseases. The phenotype is progressive. Effective surgical therapy and standardized follow-up programs have led to an improved lifespan for the affected individuals. Selective angiotensin II, type 1 (AT1) blockers may improve several manifestations of MFS, but the outcome of clinical trials is presently unknown. This review describes the importance of a coordinated strategy for diagnosis, treatment and follow-up.

AB - Marfan syndrome (MFS) and MFS-related diseases are inherited connective tissue disorders involving several organ systems. The diagnosis of MFS is difficult as the many symptoms overlap with those of other systemic connective tissue diseases. The phenotype is progressive. Effective surgical therapy and standardized follow-up programs have led to an improved lifespan for the affected individuals. Selective angiotensin II, type 1 (AT1) blockers may improve several manifestations of MFS, but the outcome of clinical trials is presently unknown. This review describes the importance of a coordinated strategy for diagnosis, treatment and follow-up.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 173

SP - 337

EP - 342

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 5

ER -

Kliniske aspekter af Marfans syndrom

Abstract

Access to Document

Fingerprint

Cite this